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ABSTRACT
Objective: This study was aimed to evaluate the anti-inflammatory effect of isolated tinocrisposide and freeze-dried aqueous extract of Tinospora crispa stems on human red blood cell (HRBC) by increasing membrane stability in vitro models.
Methods: Anti-inflammatory effect of tinocrisposide and FDAETCS was evaluated by in vitro HRBC membrane stabilization method. The study was separated into two steps which were a hemolytic and a membrane stabilization experiment. The hemoglobin that was released throughout the 
damaged erythrocytes membrane was then quantified at the wavelength of (λ) 560 nm.
Results: The hemoglobin in the HBRC supernatant that treated with tinocrisposide at concentration of 100, 200, 400, 600, 800, and 1000 μg/ml 
showed an absorbance at λ 560 nm of 0.060, 0.061, 0.071, 0.072, 0.075, and 0.0793, respectively, and the calculated hemolysis percentage was 0.032, 
0.097, 1.203, 1.236, 1.641, and 2.079%, respectively. We found a linear correlation between concentration and hemolytic activity of tinocrisposide, 
with regression equation, y=0.0023x−0.1312 (r=0.929). Meanwhile, the HBRC supernatant that treated with FDAETCS at concentration of 100, 200, 
400, 600, and 800 μg/ml showed an absorbance at λ 560 nm of 0.063, 0.064, 0.066, 0.067, and 0.077, respectively, and revealed the hemolytic 
percentage of 0.347, 0.473, 0.693, 0.992, and 1.896%, respectively. It also gave a linear correlation between FDAETCS concentration and hemolytic 
activity percentage, with regression equation, y=0.002x+0.0222 (r=0.895). Moreover, in HRBC membrane stability experiment, tinocrisposide 
concentration of 100, 200, 400, 800, and 1000 μg/ml gave absorbance at λ 560 nm of 0.818, 0.808, 0.798, 0.789, 0.773, and 0.761, respectively, and 
calculated HRBC membrane stabilization activity as much as 5.437, 6.533, 7.707, 8.748, 10.597, and 12.100%, respectively. Meanwhile, the positive 
control ibuprofen 25 μg/ml only exerted the membrane stability of 5.620%. It was found a linear correlation between tinocrisposide concentration 
and membrane stability percentage, with the regression equation, y=0.0072x+4.8312 (r=0.9932). Treated FDAETCS in the concentration of 100, 
200, 400, and 800 μg/ml gave the absorbance at λ 560 nm of 0.802, 794, 0.777, 0.791, and 0.792, with stability membrane percentage of 7.283, 
8.208, 10.944, 8.555, and 8.401%, respectively. It can be seen that the FDAETCS concentrations and its hemolytic percentage showed a parabolic 
relationship, which gave a maximum at a concentration of the extract of 400 mg/ml with membrane stabilizing of 10.944%.
Conclusion: It can be concluded that tinocrisposide and FDAETCS have an anti-inflammatory activity by increase the membrane stability of lysosome cell that has equal physiological properties with erythrocytes membrane cell and it has no hemolytic activity.
Keywords: Anti-inflammatory, Hemolytic, Human red blood cell, Membrane stabilization, Tinocrisposide, Tinospora crispa.
INTRODUCTION
Tinospora crispa is a climber plant widely distributed from the 
Southwestern part of China to Southeast Asia including Indonesia, 
Malaysia, Vietnam, Thailand, and India. It naturally occurs in primary 
rainforests or mixed deciduous forests up to 1000 m above sea level [1]. 
T. crispa is well known as a bitter medicinal plant called Brotowali, Akar 
Seruntun, or Andawali in Indonesia, Akar Patawali in Malaysia, and 
Makabuhay in Philippine. A decoction of the stems has been traditionally 
used for the treatment of gout, diabetes, malaria, fever, wound healing, 
and hypertension, and scientifically reported as an analgesic and anti-
inflammatory agents [2].
T. crispa has been demonstrated to possess antioxidant, 
antiproliferative [3], antinociceptive [4], anti-inflammatory [5], 
antibacterial [6], antifilarial, antimalarial, antipyretic [7], and 
antihyperglycemic activities [8]. In our previous study from methanol extract of dried pulverized T. crispa stems, tinocrisposide (C
27
H
36
O11) 
has been isolated, a furanoditerpene glycoside with a very bitter 
taste (Fig. 1) [9]. Furthermore, in our previous research, various 
concentrations of tinocrisposide were tested against the LPS-
stimulated RAW 264.7 cells, and the results showed the decrease of 
NO level production in concentration activity-dependent manner, 
with half-maximal inhibition concentration of 46.92 μM. Thus, it can be developed as anti-inflammatory candidate drug because NO is a 
reactive nitrogen species which is produced by NO synthase [10]. S. Chanda and A.R. Juvekar have tested in vitro anti-inflammatory activity of various concentrations of syringic acid by protein denaturation and human red blood cell (HRBC) membrane stabilization assay. The reference drugs used in experiments were aspirin and diclofenac 
sodium [11]. Meanwhile, Shamsi et al. studied anti-inflammatory 
activity of Joshanda, a polyherbal Unani formulation consists of seven plant ingredients by albumin denaturation inhibition experiment used 
aspirin as a reference compound [12]. In the current research, we are trying to prove the anti-inflammatory activity of tinocrisposide that can exert the increasing of HRBC membrane stability.
Inflammation is a normal protective response to tissue injury 
caused by physical trauma, destructive chemicals, or microbiological 
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agents [13]. It is characterized by an alteration of immune system [14]. The inflammatory process is very closely related to wound healing. 
Inflammation and repair are a continuous process in wound healing involving inflammatory cells and enzymes. Cyclooxygenase (COX) 
family enzyme – COX-1 and COX-2 – is widely studied in inflammation 
disorder and critically responsible in the illness incident [15].
The inflammation, in general, is treated by nonsteroidal anti-
inflammatory drugs (NSAIDs) and steroidal anti-inflammatory drugs which are useful for reducing swelling and pain from inflammation. 
NSAIDs inhibit the COX enzyme which caused the conversion of 
arachidonic acid to prostaglandin become disrupted [16]. These drugs have a risk of gastrointestinal toxicity, cardiac toxicity, and others for 
prolonged use [17] so that traditional medicine or treatment from nature can be used as an alternative.
MATERIALS AND METHODS
Plant materials
T. crispa was collected from Padang, Indonesia. The plant specimens were properly identified and authenticated by Dr. Nurainas at the 
Department of Biology, Faculty of Science, Andalas University.
Instruments
UV lamp (Merck, Germany), pH meter, column chromatography 
(Pyrex), micropipette (Socorex), rotary evaporator (Bűchi), UV-visible 
spectrophotometer (Hitachi U-2910), Fourier-transform infrared 
spectroscopy (FTIR) Spectrum One (PerkinElmer), freeze dryer (Christ, 
Germany), water bath (Eyela SB-1000), centrifuge (Universal 32 R, 
Hettich Zentrifugen, USA), incubator (Thermo Scientific), microplate 
reader (BioRad × Mark™), Falcon tube, Eppendorf tube, 96-well plate 
(Iwaki), and EDTA vacuum tube were used.
Materials
T. crispa stem, dichloromethane (DCM), methanol pro analysis (Merck), 
ethyl acetate (Merck), hexane (Merck), acetic acid (Merck), silica gel 60 F
254
 (Merck, Germany), TLC, sodium dodecyl sulfate (Sigma-Aldrich), 
isotonic NaCl solution (PT Widatra Bhakti), dimethyl sulfoxide (Thermo 
Fisher Scientific, USA), distilled water, ibuprofen, and human blood were used.
Freeze-dried aqueous extract Tinospora crispa stems (FDAETPS) 
preparation
Freshly collected stems were cut, shade-dried for 2–3 days, and ground 
into powder. It was then gently boiled with distilled water (1:10) for 
30 min, filtered, and allowed to cool at room temperature. The filtrate 
was then freeze-dried at −50°C and 0.1 atm for 9 h, and stored at 4°C before use.
Tinocrisposide isolation
The stems were cut, shade-dried, ground into powder, and macerated 
using methanol 3 times for 3 days each at room temperature. The extracts then evaporated under reduced pressure using a rotary 
evaporator to yield crude extracts. The extracts were dissolved in 5% 
acetic acid and allowed overnight, decanted, and then partitioned, 
sequentially, with hexane and DCM. Each fraction was evaporated 
and dried to yield n-hexane, DCM fractions. The DCM fractions then 
subjected into column chromatography over silica gel 60 and eluted 
using step gradient elution (3–8%) system with the mixture of DCM 
and methanol (3–8% methanol) which were combined on the basis of thin-layer chromatography (TLC) evaluation. TLC was carried out 
using the mixture of MeOH: DCM (1:9) as a solvent system and the fractions with same Rf values were combined and further purified by column chromatography to obtain tinocrisposide as white amorphous 
powder [16]. The powder then identified using TLC, ultraviolet 
spectrophotometry, and FTIR spectroscopy.
In vitro hemolytic testBlood from the healthy human volunteer who had not taken any 
NSAIDs for 2 weeks before the experiment was collected using 
vacutainer tube EDTA, mixed with isotonic NaCl solution, and 
centrifuged at 3000 rpm for 5 min. The packed cells were washed 
with isosaline and a 5% HRBC suspension was made. Tinocrisposide 
(100, 200, 400, 600, 800, and 1000 µg/ml) and FDAETCS (100, 200, 
400, 600, and 800 µg/ml) were prepared in a distilled water. 0.5 ml 
of sample was mixed with 0.5 ml HRBC suspension in Eppendorf 
tubes and incubated at 37°C for 1 h [18]. After incubation, the tubes 
were centrifuged at 1000 rpm for 5 min and the supernatant was 
transferred into 96-well plate. The absorbance of hemoglobin in the 
supernatant was measured at a wavelength, λ of 560 nm. As a positive Fig. 1: Chemical structure of tinocrisposide [10]
Table 1: Absorbance value of tinocrisposide and FDAETCS on hemolytic activity test
Sample Concentration (μg/ml) Absorbance
1 2 3 Mean±SDTinocrisposide 100
200
400
600
800
1000
0.058
0.061
0.068
0.068
0.073
0.074
0.059
0.064
0.071
0.079
0.074
0.082
0.063
0.058
0.074
0.069
0.079
0.082
0.060±0.002
0.061±0.003
0.071±0.002
0.072±0.007
0.075±0.003
0.079±0.005FDAETCS 100
200
400
600
800
0.063
0.064
0.066
0.063
0.079
0.062
0.062
0.070
0.067
0.077
0.065
0.066
0.063
0.071
0.076
0.063±0.002
0.064±0.002
0.066±0.004
0.067±0.002
0.077±0.002
Negative control (0.9% NaCl) 0.060 0.061 0.060 0.060±0.001
Positive control (5% SDS) 0.939 1.007 0.977 0.974±0.034
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control, 5% SDS was employed and an isotonic NaCl solution was used 
as a negative control. Measurements were replicated 3 times for each 
concentration [19]. The hemolytic activity was calculated with the 
following equation:
é ù-= ´ê ú-ê úë û
1 2
3 2
A A
% Hemolytic   100%A A
Where, A1=Absorbance of test sample
A2=Absorbance of negative control
A3=Absorbance of positive control
In vitro anti-inflammatory testThis study was conducted using the HRBC membrane stabilization method. Blood from the healthy human volunteer who had not taken 
any NSAIDs for 2 weeks before the experiment was collected using vacutainer tube EDTA. Blood samples were mixed with isotonic NaCl 
solution and centrifuged at 3000 rpm for 5 min. The packed cells were 
washed with isosaline and a 10% HRBC suspension was prepared [20]. 
Tinocrisposide (100, 200, 400, 600, 800, and 1000 µg/ml) and freeze-
dried aqueous extract (2000, 1000, 800, 600, 400, and 100 µg/ml) were dissolved in a distilled water. Reaction mixtures consisted of 1 ml 
test sample, 0.5 ml of HRBC suspension, and 1.5 ml distilled water. 
It was incubated at 37°C for 30 min and centrifuged at 3000 rpm. The hemoglobin content of the supernatant solution was measured 
spectrophotometrically at a wavelength (λ) of 560 nm. Measurements 
were replicated 3 times for each concentration. Ibuprofen that used as a standard and a control was made by substituting the test samples with 
isosaline [21]. The percentage of HRBC membrane stabilization was 
calculated using the following equation:
é ù
- ê ú
ë û
ODsample
% Stability=100  × 100%ODcontrol
Table 2: Hemolytic activity percentage of tinocrisposide and 
FDAETCS on HRBC
Sample Concentration (μg/ml) Hemolytic activity (%)Tinocrisposide 100
200
400
600
800
1000
0.032
0.097
1.203
1.236
1.641
2.079FDAETCS 100
200
400
600
800
0.347
0.473
0.693
0.992
1.896
% SDS 5 100
HRBC: Human red blood cell
Fig. 2: Diagram of hemolytic activity percentage of tinocrisposide and FDAETCS on HRBC
Table 3: Absorbance value of tinocrisposide and FDAETCS on HRBC membrane stabilization method
Tinocrisposide Concentration (μg/ml) Absorbance
1 2 3 Mean±SD
100
200
400
600
800
1000
0.817
0.789
0.777
0.803
0.741
0.734
0.819
0.798
0.820
0.780
0.788
0.752
0.817
0.838
0.798
0.785
0.791
0.796
0.818±0.001
0.808±0.033
0.798±0.022
0.789±0.012
0.773±0.028
0.761±0.032FDAETCS 100
200
400
600
800
0.799
0.781
0.784
0.724
0.747
0.800
0.792
0.789
0.795
0.786
0.807
0.808
0.804
0.855
0.753
0.802±0.004
0.794±0.014
0.777±0.010
0.791±0.066
0.792±0.021
Ibuprofen 6.25
12.5
25
0.841
0.836
0.821
0.812
0.870
0.852
0.852
0.792
0.776
0.835±0.021
0.832±0.039
0.816±0.038Control 0.815 0.901 0.879 0.865±0.045
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Data analysis
All data were expressed as means ± standard deviation of result obtained from three independent experiments. Statistical analysis was performed using paired sample t-test. P<0.05 was considered 
statistically significant. The statistical package IBM SPSS Statistics 
Version 21 for Windows was used in the analysis.
RESULTS AND DISCUSSION
In vitro hemolytic testThe hemoglobin in the HBRC supernatant that treated with 
tinocrisposide at concentration of 100, 200, 400, 600, 800, and 
1000 μg/ml showed an absorbance of 0.060, 0.061, 0.071, 0.072, 0.075, 
and 0.0793, respectively. Meanwhile, the HBRC supernatant that treated 
with FDAETCS at concentration of 100, 200, 400, 600, 800, 1000, and 
2000 μg/ml showed an absorbance of 0.063, 0.064, 0.066, 0.067, and 
0.077, respectively (Table 1).The percentage of calculated hemolytic activity of various concentrations of tinocrisposide and FDAETCS on HRBC is presented in Table 2.Data in Table 2 showed that hemolytic activity percentage of 
tinocrisposide in the concentration of 100, 200, 400, 600, 800, and 1000 
μg/ml on HRBC was 0.032, 0.097, 1.203, 1.236, 1.641, and 2.079%, 
respectively. We found a linear correlation between tinocrisposide 
concentration and hemolytic activity percentage, with regression 
equation, y=0.0023x−0.1312, and coefficient correlation, R=0.929. The same condition occurs in the FDAETCS that at the concentration of 
100, 200, 400, 600, and 800 μg/ml showed the hemolytic percentage 
of 0.347, 0.473, 0.693, 0.992, and 1.896%, respectively. It also gave a linear correlation between FDAETCS concentration and hemolytic 
activity percentage, with regression equation, y=0.002x+0.0222, and 
coefficient correlation, R=0.895.
Fig. 2 showed a clear comparison of hemolytic activity between tinocrisposide and FDAETCS in various concentrations. Hemolytic 
percentage with a value of <10% was interpreted as non-hemolytic, 
and a value of >25% was considered showing hemolytic effect. From 
the experiments, it is showed that tinocrisposide and FDAETCS have 
no hemolytic effect with a percentage value of <10% and no toxicity on HRBC so that this compound can later be used for drug formulations. 
Erythrocyte membrane is analogous to the lysosomal membrane, so compounds that caused a damage to erythrocyte membrane will also 
damage lysosomal membrane [22].
In vitro anti-inflammatory testTinocrisposide and FDAETCS were tested if they are able to prevent water-induced lysis of red blood cells using membrane stabilization assay. The result of the HRBC membrane stabilization test is shown in Table 3.Table 3 showed that by treating tinocrisposide in the concentration of 
100, 200, 400, 800, and 100 μg/ml on HRBC membrane stabilization 
experiment will give the absorption of hemoglobin at wavelength, λ 
560 nm by 0.818, 0.808, 0.798, 0.789, 0.773, and 0.761, respectively, 
with stability membrane by 5.437, 6.533, 7.707, 8.748, 10.597, and 
12.100%, respectively. Meanwhile, the positive control ibuprofen 
25 μg/ml only exerted the membrane stability of 5.620% (Table 4). 
We found a linear correlation between tinocrisposide concentration 
and membrane stability percentage, with the regression equation, 
y=0.0072x+4.8312, and the coefficient correlation, R=0.9932 (Fig. 4).Data in Table 3 showed that by treating tinocrisposide in the 
concentration of 100, 200, 400, 800, and 1000 μg/ml on HRBC membrane stabilization experiment will give the absorbance of 
hemoglobin at wavelength (λ) 560 nm by 0.802, 794, 0.777, 0.791, and 
0.792, respectively, with stability membrane by 7.283, 8.208, 10.944, 
8.555, and 8.401%, respectively. It can be seen that the relationship 
between FDAETCS and its membrane stability percentage is parabolic, 
which gave a maximum at a concentration of the extract of 400 mg/ml 
with membrane stabilizing of 10.944%. This phenomenon is assumed because the extract also contains other compounds that can cause inflammatory or hemolysis of membrane erythrocytes. Tinocrisposide 
at the concentration of 100 μg/ml had HRBC membrane stability 
of 5.437% that close to membrane stability of the positive control, 
ibuprofen at the concentration of 25 μg/ml that revealed membrane 
stability of 5.620%. It means at those concentrations the efficacy of 
tinocrisposide was 96.74% of ibuprofen. If membrane stability of 
tinocrisposide compared to FDAETCS membrane stability, it can be seen 
an interesting phenomenon, namely, FDAETCS in the level concentration 
of 100–400 μg/ml showed higher efficacy then tinocrisposide, but in 
the higher concentration, tinocrisposide revealed evidently higher efficacy than FDAETCS did (Table 4 and Fig. 3).
Table 4: Membrane stability percentage of various 
concentrations of tinocrisposide and FDAETCS
Sample Concentrations (μg/ml) Membrane 
stability (%)Tinocrisposide 100
200
400
600
800
1000
5.437
6.533
7.707
8.748
10.597
12.100FDAETCS 100
200
400
600
800
7.283
8.208
10.944
8.555
8.401
Ibuprofen 25 5.620
Fig. 3: Membrane stability percentage (%) of tinocrisposide, FDAETCS, and ibuprofen
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Fig. 4: Diagram between tinocrisposide concentrations versus 
membrane stability percentage
Anti-inflammatory agents control the biochemical processes involved during the inflammatory response by stabilizing the membranes 
of lysosomes [18]. The erythrocyte membrane is analogous to the 
lysosomal membrane, and its stabilization implies that tinocrisposide 
and FDAETCS may as well stabilize lysosomal membranes [23]. Stabilization of lysosomal membrane is important in limiting the inflammatory response by preventing the release of lysosomal constituents of activated neutrophils such as bactericidal enzymes 
and proteases, which cause further inflammation and damage on 
extracellular release [24].
In this study, distilled water was used as an inductor that triggers hemolysis that can cause the release of inflammatory mediators. By 
adding 1.5 ml of distilled water into the well plate, it will decrease an 
osmotic pressure solution outside of the erythrocyte cell, while in the 
cell, it remains equivalent to 0.9% NaCl solution. Then, the water from 
outside of the cell will move into the cell, across the erythrocytes cell 
membrane which functions as a semipermeable membrane, this causes 
the swelling of the cell, and eventually rupture and hemolysis. In human 
body, an inflammatory mediator actually plays an important role in preventing the spread of infection and is also needed to repair tissue 
damage [18]. However, excessive inflammatory mediators can cause 
tissue damage and chronic inflammation [25].
CONCLUSION
It can be concluded that tinocrisposide and FDAETPS stem have an anti-inflammatory activity by increase the membrane stability of lysosome cell that has equal physiological properties with erythrocytes membrane 
cell and it has no hemolytic activity; therefore, tinocrisposide can be promoted and developed as a new anti-inflammatory drug candidate.
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